Please login to the form below

Not currently logged in
Email:
Password:

Philippe Calais appointed CEO of Antisense Pharma

Joins as German biopharma aims to take cancer drug trabedersen to phase I

Philippe Calais - AntisenseDr Philippe Calais has joined the German biopharma Antisense Pharma as CEO.

Dr Calais replaces interim CEO Dr Hubert Heinrichs, who has held the position in addition to his role as chief medical officer since July, 2011.

One of his main tasks will be to ensure funding for the development of cancer drug trabedersen, which is planned to start phase I studies as a second-line treatment of pancreatic cancer.

“With Dr Calais, Antisense Pharma has gained an experienced global player in the pharmaceutical sector for its management board,” said Dr Heinrichs.

“During his professional career, he has been actively involved in all stages of the development of medicinal products, from discovery to clinical development, registration and commercialisation.”

This experience includes spells at Roche, where he was business unit head strategic marketing, and ICI Pharmaceuticals.

Other previous roles include CEO and president of Ambrilia Biopharma, president of global business at Neurochem and general manager at Servier Canada.

His most recent position was president and CEO of Canada-based Univalor.

“I am proud and honoured to join Antisense Pharma to lead the company's efforts in the new strategic direction,” Dr Calais commented. “Trabedersen's development package convinced me of the value of this drug candidate as I see its great potential in the fight against aggressive tumours.”

18th May 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Red Health

Red Health was formed in 2007 to bring something fresh to the healthcare PR world. Our approach was simple –...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics